Feb. 20 at 2:59 PM
$HURA Acute Myeloid Leukemia is an aggressive blood cancer where many patients relapse despite available therapies.
Current menin inhibitors have shown promise in patients with leukemia that has either relapsed or failed to respond to primary treatment, but responses are often limited and short-lived.
TuHURA’s TBS-2025 targets VISTA, a checkpoint protein that may help leukemia cells escape immune detection. Blocking this pathway could help the immune system better recognize and attack leukemic cells.
“With strong scientific rationale, we believe this combination may meaningfully improve complete response rates,” said Dr. James Bianco, CEO.
As TuHURA advances TBS‑2025 toward its upcoming clinical milestones, the company remains committed to building long‑term value through scientific rigor, operational discipline, and a clear focus on patient outcomes.
We invite our retail investors to stay engaged as the company moves forward on this important journey.
